Compare GTY & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTY | OGN |
|---|---|---|
| Founded | 1955 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | GTY | OGN |
|---|---|---|
| Price | $29.83 | $8.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.25 | $14.10 |
| AVG Volume (30 Days) | 465.8K | ★ 6.9M |
| Earning Date | 02-11-2026 | 02-12-2026 |
| Dividend Yield | ★ 6.54% | 0.98% |
| EPS Growth | ★ 10.25 | N/A |
| EPS | 1.28 | ★ 1.91 |
| Revenue | $214,194,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $6.51 | N/A |
| Revenue Next Year | $9.79 | N/A |
| P/E Ratio | $23.21 | ★ $4.29 |
| Revenue Growth | ★ 8.17 | N/A |
| 52 Week Low | $25.39 | $6.18 |
| 52 Week High | $32.17 | $17.23 |
| Indicator | GTY | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 43.82 |
| Support Level | $28.72 | $8.17 |
| Resistance Level | $30.02 | $8.53 |
| Average True Range (ATR) | 0.50 | 0.44 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 68.75 | 5.12 |
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.